Search

Your search keyword '"Fabo, Dániel"' showing total 42 results
Start Over Author "Fabo, Dániel" Language english
42 results on '"Fabo, Dániel"'

12. EEG in fitness to drive evaluations in people with epilepsy — Considerable variations across Europe

Author

Markhus, Rune, Henning, Oliver, Molteberg, Ellen, Hećimović, Hrvoje, Ujvari, Akos, Hirsch, Edouard, Rheims, Sylvain, Surges, Rainer, Malmgren, Kristina, Rüegg, Stephan, Gil-Nagel, Antonio, Roivainen, Reina, Picard, Fabienne, Steinhoff, Bernhard, Marusic, Petr, Mostacci, Barbara, Kimiskidis, Vasilios K., Mindruta, Ioana, Jagella, Caroline, Mameniškienė, Rūta, Schulze-Bonhage, Andreas, Rosenow, Felix, Kelemen, Anna, Fabo, Daniel, Walker, Matthew C., Seeck, Margitta, Krämer, Günter, Arsene, Oana Tarta, Krestel, Heinz, and Lossius, Morten

Published
2020
Full Text
View/download PDF

13. The generation and propagation of the human alpha rhythm

Author

Halgren, Milan, Ulbert, István, Bastuji, Hélène, Fabó, Dániel, Erőss, Lorand, Rey, Marc, Devinsky, Orrin, Doyle, Werner K., Mak-McCully, Rachel, Halgren, Eric, Wittner, Lucia, Chauvel, Patrick, Heit, Gary, Eskandar, Emad, Mandell, Arnold, and Cash, Sydney S.

Published
2019

19. Current practices in long-term video-EEG monitoring services: A survey among partners of the E-PILEPSY pilot network of reference for refractory epilepsy and epilepsy surgery

Author

Kobulashvili, Teia, Höfler, Julia, Dobesberger, Judith, Ernst, Florian, Ryvlin, Philippe, Cross, J Helen, Braun, Kees, Dimova, Petia, Francione, Stefano, Hecimovic, Hrvoje, Helmstaedter, Christoph, Kimiskidis, Vasilios K., Lossius, Morten Ingvar, Malmgren, Kristina, Marusic, Petr, Steinhoff, Bernhard J., Boon, Paul, Craiu, Dana, Delanty, Norman, Fabo, Daniel, Gil-Nagel, Antonio, Guekht, Alla, Hirsch, Edouard, Kalviainen, Reetta, Mameniskiené, Ruta, Özkara, Çiğdem, Seeck, Margitta, Rubboli, Guido, Krsek, Pavel, Rheims, Sylvain, and Trinka, Eugen

Published
2016
Full Text
View/download PDF

21. Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Drug-Resistant Epilepsy in the MORE Multicenter Patient Registry

Author

Peltola, Jukka, Colon, Albert J., Pimentel, José, Coenen, Volker A., Gil-Nagel, Antonio, Gonçalves Ferreira, António, Lehtimäki, Kai, Ryvlin, Philippe, Taylor, Rod S., Ackermans, Linda, Ardesch, Jacqueline, Bentes, Carla, Bosak, Magdalena, Burneo, Jorge G., Chamadoira, Clara, Elger, Christian E., Erőss, Loránd, Fabo, Dániel, Faulkner, Howard, Gawlowicz, Jacek, Gharabaghi, Alireza, Iacoangeli, Maurizio, Janszky, Jozsef, Järvenpää, Soila, Kaufmann, Elisabeth, Kho, Kuan H., Kumlien, Eva, Laufs, Helmut, Lettieri, Christian, Linhares, Paulo, Noachtar, Soheyl, Parrent, Andrew, Pataraia, Ekaterina, Patel, Nikunj K., Peralta, Ana, Rácz, Attila, Rainha Campos, Alexandre, Rego, Ricardo, Ricciuti, Riccardo A., Rona, Sabine, Rouhl, Rob P.W., Schulze-Bonhage, Andreas, Schuurman, Rick, Sprengers, Mathieu, Sufianov, Albert, Temel, Yasin, Theys, Tom, Van Paesschen, Wim, Van Roost, Dirk, Vaz, Rui, Vonck, Kristl, Wagner, Louis, Zwemmer, Jack, Abouihia, Abdallah, Brionne, Thomas C., Gielen, Frans, Boon, Paul A.J.M., Tampere University, Clinical Medicine, Department of Neurosciences and Rehabilitation, and Repositório da Universidade de Lisboa

Subjects
Medicine and Health Sciences, Neurology (clinical), 3124 Neurology and psychiatry
Abstract

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited., Background and objectives: The efficacy of deep brain stimulation of the anterior nucleus of the thalamus (ANT DBS) in patients with drug-resistant epilepsy (DRE) was demonstrated in the double-blind Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy randomized controlled trial. The Medtronic Registry for Epilepsy (MORE) aims to understand the safety and longer-term effectiveness of ANT DBS therapy in routine clinical practice. Methods: MORE is an observational registry collecting prospective and retrospective clinical data. Participants were at least 18 years old, with focal DRE recruited across 25 centers from 13 countries. They were followed for at least 2 years in terms of seizure frequency (SF), responder rate (RR), health-related quality of life (Quality of Life in Epilepsy Inventory 31), depression, and safety outcomes. Results: Of the 191 patients recruited, 170 (mean [SD] age of 35.6 [10.7] years, 43% female) were implanted with DBS therapy and met all eligibility criteria. At baseline, 38% of patients reported cognitive impairment. The median monthly SF decreased by 33.1% from 15.8 at baseline to 8.8 at 2 years (p < 0.0001) with 32.3% RR. In the subgroup of 47 patients who completed 5 years of follow-up, the median monthly SF decreased by 55.1% from 16 at baseline to 7.9 at 5 years (p < 0.0001) with 53.2% RR. High-volume centers (>10 implantations) had 42.8% reduction in median monthly SF by 2 years in comparison with 25.8% in low-volume center. In patients with cognitive impairment, the reduction in median monthly SF was 26.0% by 2 years compared with 36.1% in patients without cognitive impairment. The most frequently reported adverse events were changes (e.g., increased frequency/severity) in seizure (16%), memory impairment (patient-reported complaint, 15%), depressive mood (patient-reported complaint, 13%), and epilepsy (12%). One definite sudden unexpected death in epilepsy case was reported. Discussion: The MORE registry supports the effectiveness and safety of ANT DBS therapy in a real-world setting in the 2 years following implantation. Classification of evidence: This study provides Class IV evidence that ANT DBS reduces the frequency of seizures in patients with drug-resistant focal epilepsy., The MORE registry was sponsored and funded by Medtronic, plc.

Published
2023

41. Phase Segregation of Medial Septal GABAergic Neurons during Hippocampal Theta Activity.

Author

Borhegyi, Zsolt, Varga, Viktor, Sziágyi, Nóra, Fabo, Dániel, and Freund, Tamás F.

Subjects
GABA, NEURONS, THETA rhythm, SEPTUM (Brain), SYNAPSES
Abstract

Septo-hippocampal GABAergic neurons immunoreactive for parvalbumin are thought to play a crucial role in the generation of hippocampal theta oscillations associated with a specific stage of memory formation. Here we use in vivo juxtacellular recording and filling in the medial septum followed by immunocytochemical identification of the recorded cells containing parvalbumin to determine their firing pattern, phase relationship with hippocampal theta, morphology, and to thereby reveal their involvement in the generation of hippocampal theta activity. We have demonstrated that GABAergic medial septal neurons form two distinct populations exhibiting highly regular bursting activity that is tightly coupled to either the trough (178°) or the peak (330°) of hippocampal theta waves. Additionally, different types of bursting as well as nonbursting activity patterns were also observed. The morphological reconstruction of theta-bursting neurons revealed extensive axon arbors of these cells with numerous local collaterals establishing symmetrical synapses; thus, synchrony among the septal pacemaker units may be brought about by their recurrent collateral interactions. Long projecting axons could also be found running dorsally toward the hippocampus and ventrally in the direction of basal forebrain regions. We conclude that GABAergic neurons in the medial septum, which are known to selectively innervate hippocampal interneurons, are in a position to induce rhythmic disinhibition in the hippocampus and other theta-related subcortical areas at two different phases of hippocampal theta. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

42. Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Drug-Resistant Epilepsy in the MORE Multicenter Patient Registry.

Author

Peltola J, Colon AJ, Pimentel J, Coenen VA, Gil-Nagel A, Gonçalves Ferreira A, Lehtimäki K, Ryvlin P, Taylor RS, Ackermans L, Ardesch J, Bentes C, Bosak M, Burneo JG, Chamadoira C, Elger CE, Erőss L, Fabo D, Faulkner H, Gawlowicz J, Gharabaghi A, Iacoangeli M, Janszky J, Järvenpää S, Kaufmann E, Kho KH, Kumlien E, Laufs H, Lettieri C, Linhares P, Noachtar S, Parrent A, Pataraia E, Patel NK, Peralta AR, Rácz A, Campos AR, Rego R, Ricciuti RA, Rona S, Rouhl RPW, Schulze-Bonhage A, Schuurman R, Sprengers M, Sufianov A, Temel Y, Theys T, Van Paesschen W, Van Roost D, Vaz R, Vonck K, Wagner L, Zwemmer J, Abouihia A, Brionne TC, Gielen F, and Boon PAJM

Subjects
Humans, Female, Child, Adolescent, Male, Quality of Life, Retrospective Studies, Prospective Studies, Thalamus, Seizures etiology, Registries, Deep Brain Stimulation adverse effects, Epilepsy etiology, Drug Resistant Epilepsy therapy, Anterior Thalamic Nuclei
Abstract

Background and Objectives: The efficacy of deep brain stimulation of the anterior nucleus of the thalamus (ANT DBS) in patients with drug-resistant epilepsy (DRE) was demonstrated in the double-blind Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy randomized controlled trial. The Medtronic Registry for Epilepsy (MORE) aims to understand the safety and longer-term effectiveness of ANT DBS therapy in routine clinical practice., Methods: MORE is an observational registry collecting prospective and retrospective clinical data. Participants were at least 18 years old, with focal DRE recruited across 25 centers from 13 countries. They were followed for at least 2 years in terms of seizure frequency (SF), responder rate (RR), health-related quality of life (Quality of Life in Epilepsy Inventory 31), depression, and safety outcomes., Results: Of the 191 patients recruited, 170 (mean [SD] age of 35.6 [10.7] years, 43% female) were implanted with DBS therapy and met all eligibility criteria. At baseline, 38% of patients reported cognitive impairment. The median monthly SF decreased by 33.1% from 15.8 at baseline to 8.8 at 2 years ( p < 0.0001) with 32.3% RR. In the subgroup of 47 patients who completed 5 years of follow-up, the median monthly SF decreased by 55.1% from 16 at baseline to 7.9 at 5 years ( p < 0.0001) with 53.2% RR. High-volume centers (>10 implantations) had 42.8% reduction in median monthly SF by 2 years in comparison with 25.8% in low-volume center. In patients with cognitive impairment, the reduction in median monthly SF was 26.0% by 2 years compared with 36.1% in patients without cognitive impairment. The most frequently reported adverse events were changes (e.g., increased frequency/severity) in seizure (16%), memory impairment (patient-reported complaint, 15%), depressive mood (patient-reported complaint, 13%), and epilepsy (12%). One definite sudden unexpected death in epilepsy case was reported., Discussion: The MORE registry supports the effectiveness and safety of ANT DBS therapy in a real-world setting in the 2 years following implantation., Classification of Evidence: This study provides Class IV evidence that ANT DBS reduces the frequency of seizures in patients with drug-resistant focal epilepsy., Trial Registration Information: MORE ClinicalTrials.gov Identifier: NCT01521754, first posted on January 31, 2012., (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results